New partnership could result in "one-size-fits-all" cancer treatment

New partnership could result in

PanARMENIAN.Net - British scientists who announced last week their discovery of a new type of cancer-killing T-cell have entered a partnership with a biotechnology company pioneering the use of Dark Antigens to develop T-cell receptor (TCR)-based immunotherapies and off-the-shelf cancer vaccines. The result—they hope—will be a “one-size-fits-all” cancer therapy, Forbes reports.

Last Monday, scientists at Cardiff University in the UK announced they had identified a new type of killer T-cell—a T-cell clone—that recognized and killed multiple different types of human cancer, while ignoring healthy, non-cancerous cells. The discovery, researchers said, offers hope of a universal cancer therapy. The researchers reported in Nature Immunology that these T-cells attacked many forms of cancer from all individuals. The T-cell clone killed lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer.

Less than a week later, the Cardiff researchers have announced they will enter a partnership with Ervaxx to eventually bring their discovery to patients.

The Cardiff University T-cell modulation group, within the Division of Infection and Immunity, studies all areas of T-cell biology including T-cell genetics, molecular biology, protein chemistry, crystallography and cell biology. The group aims to understand the genetic, biochemical and cellular mechanisms that govern T-cell responses in human diseases, such as HIV, EBV, tuberculosis autoimmunity and cancer.

T-cell therapies for cancer are the latest paradigm in cancer treatments. Current therapies include CAR-T and TCR-T, where immune cells are removed, genetically-modified and returned to a patient’s blood to seek and destroy cancer cells. Current therapies are personalized to each patient, target only a few types of blood cancer and have not been successful for solid tumors, which make up the vast majority of cancers.

 Top stories
The Prosecutor’s Office has released surveillance footage and said that one of the detainees in the case, Iveri Melashvili.
Destinations welcomed 900m fewer international tourists in January–October when compared with the same period of 2019.
Austrian authorities said at least one gunman remained on the run at 1am Vienna time on November 3.
Moderna’s proposed price would apply to the United States and other high-income countries.
Partner news